Operating Income (Loss) in USD of Greenwich LifeSciences, Inc. from Q3 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Greenwich LifeSciences, Inc. quarterly/annual Operating Income (Loss) history and change rate from Q3 2019 to Q3 2025.
  • Greenwich LifeSciences, Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was -$4.17M, a 53% decline year-over-year.
  • Greenwich LifeSciences, Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was -$19.6M, a 82% decline year-over-year.
  • Greenwich LifeSciences, Inc. annual Operating Income (Loss) for 2024 was -$16M, a 71.7% decline from 2023.
  • Greenwich LifeSciences, Inc. annual Operating Income (Loss) for 2023 was -$9.33M, a 16% decline from 2022.
  • Greenwich LifeSciences, Inc. annual Operating Income (Loss) for 2022 was -$8.04M, a 74.9% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Greenwich LifeSciences, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$19.6M -$4.17M -$1.45M -53% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$18.1M -$4.05M -$1.38M -52% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 -$16.8M -$3.28M -$745K -29.4% 01 Jan 2025 31 Mar 2025 10-Q 20 May 2025
Q4 2024 -$16M -$8.08M -$5.25M -185% 01 Oct 2024 31 Dec 2024 10-K 15 Apr 2025
Q3 2024 -$10.8M -$2.73M -$226K -9.03% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 -$10.5M -$2.66M -$914K -52.3% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025
Q1 2024 -$9.62M -$2.54M -$296K -13.2% 01 Jan 2024 31 Mar 2024 10-Q 20 May 2025
Q4 2023 -$9.33M -$2.84M +$58.7K +2.03% 01 Oct 2023 31 Dec 2023 10-K 15 Apr 2025
Q3 2023 -$9.39M -$2.5M -$120K -5.03% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024
Q2 2023 -$9.27M -$1.75M -$975K -126% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024
Q1 2023 -$8.29M -$2.24M -$252K -12.7% 01 Jan 2023 31 Mar 2023 10-Q 20 May 2024
Q4 2022 -$8.04M -$2.89M -$517K -21.8% 01 Oct 2022 31 Dec 2022 10-K 15 Apr 2024
Q3 2022 -$7.52M -$2.38M -$1.52M -175% 01 Jul 2022 30 Sep 2022 10-Q 19 Oct 2023
Q2 2022 -$6.01M -$773K -$19.9K -2.64% 01 Apr 2022 30 Jun 2022 10-Q 21 Aug 2023
Q1 2022 -$5.99M -$1.99M -$1.39M -231% 01 Jan 2022 31 Mar 2022 10-Q 22 May 2023
Q4 2021 -$4.6M -$2.38M -$1.23M -106% 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2023
Q3 2021 -$3.37M -$867K -$610K -237% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 -$2.76M -$753K -$543K -258% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022
Q1 2021 -$2.22M -$601K -$356K -146% 01 Jan 2021 31 Mar 2021 10-Q 20 May 2022
Q4 2020 -$1.86M -$1.15M 01 Oct 2020 31 Dec 2020 10-K 21 Mar 2022
Q3 2020 -$257K +$79.1K +23.6% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021
Q2 2020 -$210K 01 Apr 2020 30 Jun 2020 10-Q 13 Aug 2021
Q1 2020 -$245K 01 Jan 2020 31 Mar 2020 10-Q 20 May 2021
Q3 2019 -$336K 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020

Greenwich LifeSciences, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$16M -$6.68M -71.7% 01 Jan 2024 31 Dec 2024 10-K 15 Apr 2025
2023 -$9.33M -$1.29M -16% 01 Jan 2023 31 Dec 2023 10-K 15 Apr 2025
2022 -$8.04M -$3.44M -74.9% 01 Jan 2022 31 Dec 2022 10-K 15 Apr 2024
2021 -$4.6M -$2.73M -147% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023
2020 -$1.86M +$1.56M +45.6% 01 Jan 2020 31 Dec 2020 10-K 21 Mar 2022
2019 -$3.43M 01 Jan 2019 31 Dec 2019 10-K 31 Mar 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.